Predictive factors of clinical outcome in patients with diffuse proliferative lupus nephritis treated early by intravenous methylprednisolone pulse therapy

Renal Failure

Volumn 29, Issue 1, 2007, Pages 41-47

  Kanno, Atsuhiro ^a,b   Hotta, Osamu ^a   Yusa, Naoko ^a   Taguma, Yoshio ^a  

^a Sendai Shakaihoken Hospital   (Japan)

^b Sendai Shakaihoken Hospital   (Japan)

Author keywords

Activity Index; Chronicity Index; DPLN; Predictive factor

Indexed keywords

ALBUMIN; AZATHIOPRINE; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MIZORIBINE; STEROID;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; AVASCULAR NECROSIS; BLOOD PRESSURE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE SEVERITY; DRUG PULSE THERAPY; ERYTHROCYTE; FEMALE; FIBROSING ALVEOLITIS; HISTOLOGY; HUMAN; KIDNEY INJURY; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MONOTHERAPY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEINURIA; RANK SUM TEST; REMISSION; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; TREATMENT DURATION;

ADULT; FEMALE; GLUCOCORTICOIDS; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY; LUPUS NEPHRITIS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PROGNOSIS; PULSE THERAPY, DRUG; RETROSPECTIVE STUDIES;

EID: 33846949378     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220601038850     Document Type: Article

References (26)

1. Cameron JS. Lupus nephritis. J Am Soc Nephrol. 1999;10:413-424.
2. Baqi N, Moozami S, Singh A, Ahmad H, Bahlachandra S, Tejani A. Lupus nephritis in children: A longitudinal study of prognostic factors and therapy. J Am Soc Nephrol. 1996;7:924-929.
3. Austin HA, Muenz LR, Joyce KM, et al. Prognostic factors in lupus nephritis: Contribution of renal histologic data. Am J Med. 1983;74:382-391.
4. Schwartz MM, Bernstein J, Hill GS, Holley K, Phillips EA. Predictive value of renal pathology in diffuse proliferative lupus glomerulonephritis. Kidney Int. 1989;36: 891-896.
5. Lewis EJ, Hunsicker LG, Lan SP, Rhode RD, Lachin JM. A controlled trial of plasmapheresis therapy in severe lupus nephritis. N Engl J Med. 1992;326:1373-1379.
6. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46: 2121-2131.
7. Austin HA 3rd, Muenz LR, Joyce KM, Antonovych TT, Balow JE. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int. 1984;25:689-695.
8. Esdaile JM, Levinton C, Federgreen W, Hayslett JP, Kashgarian M. The clinical and renal biopsy predictors of long-term outcome in lupus nephritis: A study of 87 patients and review of the literature. Q J Med. 1989;72:779-833.
9. Howie AJ, Turhan N, Adu D. Powerful morphometric indicator of prognosis in lupus nephritis. Q J Med. 2003;96:411-420.
10. Schwartz MM, Lan SP, Bernstein J, Hill GS, Holley K, Lewis EJ. Role of pathology indices in the management of severe lupus glomerulonephritis. Lupus Nephritis Collaborative Study Group. Kidney Int. 1992;42:743-748.
11. Schwartz MM, Lan SP, Bernstein J, Hill GS, Holley K, Lewis EJ. Irreproducibility of the activity and chronicity indices limits their utility in the management of lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis. 1993;21:374-377.
12. Lim CS, Chin HJ, Jung YC, et al. Prognostic factors of diffuse proliferative lupus nephritis. Clin Nephrol. 1999;52:139-147.
13. Korbet SM, Lewis EJ, Schwartz MM, et al. Factors predictive of outcome in severe lupus nephritis. Am J Kidney Dis. 2000;35:904-914.
14. Weening JJ, D'Agati D, Schwartz M, et al. The classification of glomerulonephritis in systemic lupus erythematosus revised. Kidney Int. 2004;65:521-530.
15. Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J, et al. Factors predictive of outcome in severe lupus nephritis. Am J Kidney Dis. 2000;35:904-914.
16. Austin HA, Balow JE. Natural history and treatment of lupus nephritis. Semin Nephrol. 1999;19:2-11.
17. Chan TM, Tse KC, Tang CSO, Lai KN, Li FK. Long-term outcome of patients with DPLN treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus. 2005;14:265-272.
18. Pollak VE, Pirani CL. Renal histologic findings in systemic lupus erythematosus. Mayo Clin Proc 1969;44:630-644.
19. Contreras G, Tozman E, Nilay N, David M. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil,azathioprine and intravenous cyclophosphamide. Lupus. 2005;14:33-38.
20. Illei GG, Austin HA, Crane M, et al. Combination therapy with pulse cyclophophamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med. 2001;135:248-257.
21. Gourley MF, Austin HA 3rd, Scott D, et al. Methylprednisolone and cyclophophamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med. 1996;125:549-557.
22. Park MC, Park YB, Jung SY. Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophophamide pulse therapy. Lupus. 2004;13:569-574.
23. Petri M. Cyclophosphamide: new approaches for systemic lupus erythematosus. Lupus. 2004;13:366-371.
24. Moroni G, Pasquali S, Quaglini S et al. Clinical and prognostic value of serial renal biopsies in lupus nephritis. Am J Kidney Dis. 1999;34:530-539.
25. Austin HA 3rd, Boumpas DT, Vaughan EM, Balow JE. High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant. 1995;10:1620-1628.
26. Najafi CC, Korbet SM, Lewis EJ, et al. Significance of histologic patterns of glomerular injury upon long-term prognostic in severe lupus glomerulonephritis. Kidney Int. 2001;59: 2156-2163.